STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Anamorelin

Also known as

ONO-7643 · Adlumiz · anamorelin HCl

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Niche talk Systemic Oral Growth hormone axis

Systemic oral ghrelin mimetic.

What people say An oral small-molecule ghrelin mimetic discussed for stronger appetite and lean-mass support in cancer cachexia. It increases hunger, unlike appetite-suppressing weight-loss drugs; clinical lean-mass findings are not a bodybuilding guarantee. Doses people talk about
Clinical oral context~100 mg once daily

Cancer-cachexia trial/label context, with oncology care and formulation-specific food rules.

One gym account50 mg reported

Purported ONO-7643 on successive occasions; later pre-gym nausea, fatigue and breathlessness. Product unverified and route not explicit in the post.

Reported quantities, not a progression. Cancer/cachexia treatment cannot be repurposed as a fitness or cutting protocol.

Half-life & effect duration

Half-life in the body
  • Oral capsuleAbout 6–7 hours
Felt duration people report
  • Hunger assessmentsIncreased hunger reported between 30 minutes and 4 hours
  • Wear-off timeNot consistently reported
Timing context & sources
How it may feel Hunger can increase early. The gym account instead highlights nausea, fatigue and breathlessness; better sleep, mood and energy appear in multi-ingredient pill recollections, where anamorelin's contribution cannot be isolated.
Cycles people discuss Clinical studies use continuous daily oral treatment. Weeks-on/off reports and cost/caution explanations remain in the community notes, but no universal anamorelin cycling calendar is established. Timing Clinical food timing matters: Japanese cachexia labeling uses fasted dosing and a 1-hour food interval. Pre-gym and sleep-related anecdotes do not establish an ideal time or how long hunger lasts. Stacks Compared with MK-677 as another oral GH-axis appetite agent. Reported sleep/mood benefits came from multi-ingredient pills; hormonal-agent bloodwork/PCT talk is not proof anamorelin has that profile. Watch for Hyperglycemia / edema / cardiac conduction: Glucose elevation and edema are clinical safety concerns. The Japanese review also flags PR prolongation and QRS widening, with ECG precautions; subjective well-being does not rule these out. Strong CYP3A4 inhibitors are contraindicated in that labeling context.
Related
MK-677IpamorelinCJC-1295BPC-157

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 6–7 hours terminal half-life after a single 25 mg oral capsule in healthy adults.

Mean cohort estimates ranged from 6.08 to 7.03 hours under fasted conditions, separate from the 100 mg daily cachexia setting.

Small age/sex cohorts; this parent-drug clock does not quantify hunger, GH response or an individual's elimination.

Felt duration people report

Hunger was assessed from 30 minutes through 4 hours; a dependable wear-off time was not established.

Small oral trials measured hunger at scheduled points. The gym and blend reports describe effects without a clear offset.

The last pre-meal assessment is not return to baseline. The community accounts involve unverified products or multiple ingredients.

  • Anamorelin and appetite/food intake in healthy adults (2019) (opens in a new tab)Abstract: studies 101/102, dose groups and pre-prandial hunger measurements through 4 h; full text/abstract read through Europe PMC fullTextXML.Small single-centre healthy-adult studies. Hunger measurements at selected times are not a complete return-to-baseline clock or cancer efficacy guarantee.
  • First cycle update #1 — ONO-7643 account (opens in a new tab)Difficult_Pause5961 OP (May 3, 2022): first 50 mg reportedly without effects, second 50 mg before gym with nausea, fatigue and shortness of breath; visible replies read.Unverified purported ONO-7643 product. Inconsistent clock wording and no clear offset; planned MK-2866 was not yet begun in the OP. No visible later resolution was established; not a validated schedule.
  • What to expect from combo peptide? — multi-ingredient pill recollections (opens in a new tab)NashvilleSurfHouse reply: roughly 10-active pill including SARMs/anabolics/anamorelin, better rest and mood/energy; OP MHB24 response recalls sleep and return to gym after illness.Blend ingredients and identities unverified; recollection cannot isolate anamorelin. The separate Wellbutrin recollection is not an anamorelin response. Visible context read, not treated as dose consensus.

Other context in this card

What people say 5

  • Body-comp talk: Anamorelin is discussed for recomp, strength continuity, or soft-tissue recovery depending on class. forum
  • Training confound: PRs and scale changes almost always co-travel with diet phase and programming. anecdote
  • Suppression / lipid chatter: Hormonal-agent stack discussions bring bloodwork and PCT concerns even when marketed “mild.” This is background about other hormonal agents, not evidence that anamorelin itself has an androgen-suppression/PCT profile. forum
  • Cycle thinking: Fixed on/off blocks appear in broader self-experiment discussion, but they are not established as the dominant anamorelin pattern; clinical programs use continuous daily oral treatment. forumtrial
  • Appetite / LBM trials: Cachexia programs reported appetite and LBM signals. trial

Doses people talk about 4

  • Framing: Oral ghrelin-receptor agonist studied for cancer cachexia. A separate unverified ONO-7643 forum account described 50 mg on successive occasions, with nausea, fatigue and shortness of breath after the later pre-gym dose; this is not the 100 mg oncology regimen or a dose to copy. trialforum
  • Route: oral tablet/capsule trial culture — not an SC research-chem pin. trial
  • Context: studied with oncology/cachexia care, not general fitness cutting. trial
  • Clinical oral band: commonly ~100 mg once daily oral in anamorelin cachexia trials. trial

How it may feel 5

  • Days 1–7: GI and mood changes remain topics in the existing notes. One purported ONO-7643 account reported nausea, mild fatigue and shortness of breath after 50 mg before the gym. The older conditional injection-site wording concerned injectable agents generally; it is not evidence for injected anamorelin. forum
  • Day 1 / blend recollections: Route and GI logistics are not proof of benefit. Better sleep, feeling rested, happier mood and energy appear in recollections of a roughly 10-ingredient pill containing anamorelin plus SARMs/anabolic agents; those effects cannot be assigned to anamorelin. Sting belongs to the older general injectable-agent context, not a verified route here. forum
  • Days 2–7: A general side-effect observation window in the older multi-agent notes, not an established anamorelin onset/offset curve; benefits or adverse effects on blends are easy to misattribute. forum
  • Weeks 1–2: An early check-in used in broader self-logs, not a validated anamorelin efficacy checkpoint. The reviewed accounts do not establish a universal timetable. forum
  • Appetite timing: Clinical discussion describes relatively early appetite change; small healthy-adult studies detected hunger differences beginning at a 0.5-hour assessment and through the 4-hour pre-meal assessment in pooled 25/50 mg groups. That does not define how long an individual dose feels active. trial

Cycles people discuss 4

  • On/off discussion: Weeks-on / weeks-off appears in the existing self-protocol notes, with cost and caution offered as reasons rather than hard science. Prevalence in anamorelin users is not established, and these patterns differ from continuous clinical dosing. forum
  • No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
  • Clinical: Continuous daily oral in trial designs. trial
  • Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum

Timing 3

  • Timing practicalities: Training, sleep and side-effect timing appear in self-reports. Separately, the Japanese cachexia labeling describes 100 mg oral once daily fasted, with no food for at least 1 hour after dosing; that food rule is not an appetite-duration estimate or a gym protocol. forumtrial
  • Hunger timing versus PK: In small healthy-adult trials, pooled 25/50 mg oral groups reported increased hunger at assessments from 0.5 through 4 hours (not every time point significant). Four hours was the last pre-meal assessment, not a measured return to baseline; the reviewed gym/blend accounts do not establish a reproducible offset. trialforum
  • Oral PK: After a single fasted 25 mg oral capsule, mean terminal half-life ranged from 6.08 to 7.03 hours across small healthy age/sex cohorts. This is measured parent-drug elimination, not the daily schedule or how long hunger lasts. trial

More on what it is 5

  • Why people care: Appetite + lean mass pathway distinct from classic GHRP injectables. forum
  • Research posture: Educational summary of public discussion and literature themes only. forum
  • How people talk about it: Forum volume is a popularity signal for Anamorelin, not proof it works for you. forum
  • What it is: Oral small-molecule ghrelin-receptor agonist developed for cancer cachexia (appetite/LBM). It stimulates appetite; it is not the ghrelin peptide itself or an appetite-suppression drug. trial
  • Research only: Not approved advice for self-experimentation; legality and access vary by place. forum

Stacks 2

  • Vs MK-677: Compared as oral GH-axis appetite agents with different evidence bases. forum
  • Attribution: Solo runs make a personal n=1 easier to interpret than five-compound blasts. The reviewed sleep/mood/energy recollections involved roughly 10-ingredient pills with SARMs/anabolics and anamorelin; they are not evidence of synergy or a stack to follow. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 6

  • Not a cut drug: Appetite increase is the point in cachexia — opposite of dieting goals. forum
  • Injection-site caution (other injected agents): Redness, itch, lumps and bruising can accompany injectable stack components; technique and product quality matter. Anamorelin's reviewed clinical formulations are oral, so this is not evidence for an anamorelin injection route. forum
  • Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
  • Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
  • Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
  • Hyperglycemia / edema / cardiac conduction: Glucose elevation and edema are clinical safety concerns. The Japanese review also flags PR prolongation and QRS widening, with ECG precautions; subjective well-being does not rule these out. Strong CYP3A4 inhibitors are contraindicated in that labeling context. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →